Evaluation of the Efficacy and Safety of Chemotherapy in Elderly Patients with Multiple Myeloma under Different Frailty Scores.
10.19746/j.cnki.issn.1009-2137.2022.01.028
- Author:
Ru XUE
1
,
2
;
Lu CHENG
1
,
2
;
Li-Min SONG
1
,
2
;
Yan-Ping MA
3
,
4
Author Information
1. Shanxi Medical University
2. Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
3. Department of Hematology
4. Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China,E-mail: myanp18@163.com.
- Publication Type:Journal Article
- Keywords:
Charlson comorbidity index;
activity of daily living score;
bortezomib;
instrumental activity of daily living scale;
multiple myeloma
- MeSH:
Aged;
Bortezomib;
Frailty;
Humans;
Multiple Myeloma/drug therapy*;
Retrospective Studies
- From:
Journal of Experimental Hematology
2022;30(1):170-174
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To compare the efficacy and safety of different chemotherapy regimens in elderly multiple myeloma (MM) patients with different Frailty scores.
METHODS:The clinical data of elderly patients with MM were retrospectively analyzed, including age, treatment regimen, efficacy, adverse reactions, and the Frailty score included in the activity of daily living score, the instrumental activity of daily living scale and the Charlson comorbidity index. The patients were divided into fit group, mediate fit group and frail group according to the scoring standard. The treatment efficiency and adverse reaction rates of elderly MM with different physical conditions treated by different chemotherapy regimens were analyzed.
RESULTS:Among the 70 patients, the effective rates of the patients in fit group, the mediate fit group, and the frail group were 79.5%, 81%, and 40%, and the effective rates of the fit patients in double and triple groups were 54.5% and 89.3%, 70% and 90.9% for mediate fit patients, 42.9% and 33.3% for frail patients, the triple regimen in fit patients showed obvious advantages, and the difference showed statistically significant (P<0.05), while the efficacy for mediate patients and frail patients showed no significant difference. During the induction of bortezomib, the incidence of adverse reactions for the patients in the triple group (78.6%) was higher than 67.9% in the double group, and the difference showed no statistically significant (P>0.05).There was no significant difference in the 1-year overall survival rate of the patients and with molecular genetic abnormalities among each groups.
CONCLUSION:The therapeutic effect is related to the patient's physical condition. For patients with healthy physique, the triple regimen should be used first. For patients with weak physical constitution, the chemotherapy regimen with low drug toxicity should be selected for safety.
